Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Late phase II intra-arterial SM-11355 (Miriplatin Hydrate) in hepatocellular carcinoma
jRCT2080220093Phase 2
- Sponsor
- Sumitomo Pharma
- Start
- Sep 2005
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of miriplatin in hepatocellular carcinoma (HCC), sponsored by Sumitomo Pharma.
02
Drugs
miriplatin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2080220093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220093.